In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.
Heeke S, Benzaquen J, Long-Mira E, Audelan B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O, Montaudié H, Dugourd PM, Chassang M, Passeron T, Delingette H, Marquette CH, Hofman V, Stenzinger A, Ilié M, Hofman P.
Heeke S, et al. Among authors: delingette h.
Cancers (Basel). 2019 Aug 29;11(9):1271. doi: 10.3390/cancers11091271.
Cancers (Basel). 2019.
PMID: 31470674
Free PMC article.